Introduction {#s1}
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies with poor prognosis, and the incidence of HCC has been steadily rising ([@B1]). With the progress in the diagnosis and treatment of HCC, local treatment such as resection, transcatheter arterial chemoembolization (TACE), transcatheter arterial chemotherapy infusion (TACI), and radiofrequency ablation (RFA) became the standard treatment, resulting in great improvement in survival and disease control. In addition, conventional radiotherapy (RT) or stereotactic body RT (SBRT) achieved substantial tumor regression and survival as reported in various studies ([@B2]--[@B5]). Despite the development of various treatment strategies, the prognosis of HCC is still poor, and several studies are underway to find the prognostic factors to improve outcome.

Poor general condition, low hepatic functional reserve, and protein energy malnutrition causing impaired immunity and dysregulated metabolism lead to poor long-term prognosis of HCC ([@B6], [@B7]). The concept of cachexia has been commonly used to describe the general condition of such cancer patients. The agreed diagnostic criterion for cachexia was weight loss \>5%, or weight loss \>2% in individuals already showing depletion according to current bodyweight and height \[body-mass index (BMI) \<20 kg/m^2^\] or skeletal muscle mass ([@B8]). However, cachexia can sometimes be misdiagnosed because the assessment of weight change depends on patient\'s response during a physical examination ([@B9]). Furthermore, changes in body weight do not fully reflect body composition change, and weight loss is uncertain for patients with large tumor, pleural effusion, or severe body edema ([@B10]). Therefore, a more qualified indicator of this wasting condition is needed to predict the prognosis of HCC.

Sarcopenia is defined by the loss of skeletal muscle mass, quality, and strength. The causes of sarcopenia include aging, disuse (poor performance status), nutritional deficiencies, advanced organ failure, inflammatory disease, and cancer treatment-related toxicities ([@B11]). Noteworthy is that there is evidence that sarcopenia is prevalent in cancer patients, regardless of stage of disease and nutritional status ([@B12]) and it is identified as a poor prognostic factor for various types of malignancies ([@B13]--[@B16]). Particularly, sarcopenia occurs frequently in cases of HCC after treatment ([@B17]--[@B19]) and many studies on the association of HCC prognosis with sarcopenia were performed. These studies have shown that sarcopenia was an independent predictor of mortality in patients with HCC following partial hepatectomy, intra-arterial HCC therapy, or after sorafenib ([@B17]--[@B20]). However, few studies have investigated that sarcopenia is an independent predictor of prognosis in patients receiving RT for HCC.

In this study, we investigated the prevalence and prognostic significance of sarcopenia in patients that underwent RT for HCC. In addition, we also evaluated the associated factors that induce sarcopenia after RT.

Materials and Methods {#s2}
=====================

Patient Selection
-----------------

The medical records and radiology database at Gangnam Severance hospital were searched for patients with primary HCC stage I-IVB (Liver Cancer Study Group of Japan \[LCSGJ\]) that underwent RT to the liver from January 2009 to November 2016. HCC was diagnosed based on typical dynamic study findings of enhanced staining in the early phase and attenuation in the delayed phase ([@B21]). Patients who did not receive RT directly to the liver or those who did not complete RT were excluded. We evaluated 156 patients who were eligible for our study.

Treatment
---------

In this study, the aim of RT was classified as definitive, salvage, and palliative. Definitive aim meant treating the first diagnosed HCC for the purpose of complete remission. Salvage aim meant retreatment if previous local treatment of HCC failed. Palliative aim was defined as treatment for symptom control when cure was difficult to achieve.

Patients were treated with RT alone or concurrent chemoradiotherapy (CCRT). In the CCRT group, concurrent hepatic arterial infusion of 5-fluorouracil (5-FU) was delivered during RT. Most patients received conventional RT (30--70 Gy in 10--30 fractions) with 3-dimensional conformal RT (3D-CRT) or intensity-modulated RT (IMRT), and a small number of patients received SBRT (36--60 Gy in four fractions).

Treatment before RT was classified as surgery, systemic chemotherapy, or local treatment (TACE or TACI or RFA). All surgeries were partial hepatectomies, and most of the patients undergoing systemic chemotherapy received sorafenib regimen.

Definition of Sarcopenia
------------------------

Sarcopenia was identified at two-time points: pre- and post-RT. Pre-RT sarcopenia was diagnosed with data from the simulation computed tomography (CT) prior to RT, while post-RT sarcopenia was diagnosed with data from the follow-up CT taken within 3 months from the end of RT.

We retrospectively measured the cross-sectional area of muscle at the level of the third lumbar vertebra using baseline CT images. The muscles were quantified within a Hounsfield unit (HU) range of −29 to +150, and muscle boundaries were manually corrected as needed ([Figure 1](#F1){ref-type="fig"}) ([@B22], [@B23]). Then, we calculated the L3 skeletal muscle index (L3-SMI) as follows:
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Sarcopenia defined by international consensus of cancer cachexia was \<55 cm^2^/m^2^ for men and \<39 cm^2^/m^2^ for women ([@B8]). However, this is based on studies among Westerners, and different standards are needed for Asians with differences in their intrinsic muscles. Therefore, we used the Korean-specific cut off values defined in other studies. Sarcopenia was defined as an L3-SMI of \<49 cm^2^/m^2^ for men and \<41 cm^2^/m^2^ for women as proposed by Korean-specific cut off values ([@B24]).

![Segmented computed tomography (CT) images of patients with **(A)** and without **(B)** sarcopenia who had similar body mass indices. Skeletal muscle was measured using the MIM Vista software (MIM corp., version 6.1, OH, USA).](fonc-09-01075-g0001){#F1}

Data Collection
---------------

Demographic and treatment characteristics of individual patients were obtained from the medical records, including age at diagnosis, sex, tumor stage, liver enzymes, Child-Pugh classification, tumor marker, and treatment before RT. All patients underwent initial and response evaluation based on computed tomography (CT) or magnetic resonance imaging (MRI).

Height and weight were recorded at first visit to our department. The BMI grouping based on the World Health Organization criteria is as follows: BMI \<18.5 kg/m^2^ (underweight), BMI 18.5--25 kg/m^2^ (normal weight), BMI 25--30 kg/m^2^ (overweight), and BMI ≥ 30 kg/m^2^ (obesity).

Information was collected on the following variables to analyze the prognostic factors for overall survival (OS): age; sex; viral infection (hepatitis B virus, hepatitis C virus); total dose of RT; RT modality; planning target volume (PTV); CCRT; Child-Pugh classification (A vs. B + C); HCC stage at the time of RT; portal vein tumor thrombus; prior treatment (resection, chemotherapy, TACE or TACI or RFA); alpha-fetoprotein (AFP, cut off value 20 ng/mL); protein induced by vitamin K absence or antagonist-II (PIVKA-II, cut off value 40 mAU/mL); serum total protein (cut off value 6.0 g/dL); serum albumin level (cut off value 3.4 g/dL); albumin-bilirubin (ALBI) grade; and BMI. The ALBI score was derived from the formula (log~10~ bilirubin \[μmol/L\] × 0.66) + (albumin \[g/L\] × −0.0852).

Statistical Analysis
--------------------

Baseline characteristics of patients with and without sarcopenia were compared via the Pearson χ^2^ test for categorical data and independent *t*-test for continuous data.

OS was defined as the time from start of RT until death or last patient contact. OS was analyzed using the Kaplan-Meier method and log-rank test. Univariate and multivariate analyses for OS were performed with the Cox proportional hazards model. Multivariate survival analysis was conducted using the Cox proportional hazards regression, and variables with a *p* \< 0.10 in univariate analysis were included. The multivariate analysis for risk factor of post-RT sarcopenia was also performed using logistic regression analysis.

All *p*-values lower than 0.05 were considered statistically significant. Statistical analysis was performed using IBM SPSS, version 23.0 (IBM Corp., Armonk, NY, USA).

Results {#s3}
=======

Patient and Treatment Characteristics
-------------------------------------

The baseline characteristics of total 156 patients are listed in [Table 1](#T1){ref-type="table"}. For all the patients, the median L3-SMI for pre-RT was 46.4 cm^2^/m^2^ (range 29.5--66.6 cm^2^/m^2^) in men and 38.4 cm^2^/m^2^ (range 26.1--57.5 cm^2^/m^2^) in women. According to Korean-specific cut off standard, 99 patients (63.5%) had pre-RT sarcopenia; 81 patients (81.8%) were men and 18 (18.2%) women.

###### 

Characteristics of total patients with HCC and patients with HCC according to the presence of pre-RT sarcopenia.

                                                 **Total**        **Pre-RT sarcopenia**                                        
  ---------------------------- ----------------- ---------------- ----------------------- ---------------- ------- ---- ------ -------
  Age (years)                  Median            59               57                      61               0.592               
                               Range             23--87           34--80                  23--87                               
  Sex                          Male              128              82.1                    47               82.5    81   81.8   0.920
                               Female            28               17.9                    10               17.5    18   18.2   
  Etiology                     HBV               113              72.4                    39               68.4    74   74.7   0.571
                               HCV               14               9.0                     7                12.3    7    7.1    
                               Non-B, non-C      29               18.6                    11               19.3    18   18.2   
  HCC stage                    I                 3                1.9                     2                3.5     1    1.0    0.372
                               II                15               9.6                     6                10.5    9    9.1    
                               III               48               30.8                    18               31.6    30   30.3   
                               IVA               69               44.2                    24               42.1    45   45.5   
                               IVB               21               13.5                    7                12.3    14   14.1   
  Portal vein tumor thrombus   Yes               93               59.6                    35               61.4    58   58.6   0.730
                               No                63               40.4                    22               38.6    41   41.4   
  Child-Pugh score             A                 96               61.5                    40               70.1    56   56.6   0.115
                               B                 57               36.5                    16               28.1    41   41.4   
                               C                 3                1.9                     1                1.8     2    2.0    
  AFP (ng/mL)                  Median            210.4            50.2                    296.9            0.279               
                               Range             1.3--54,000      1.8--54,000             1.3--54,000                          
  PIVKA-II (mAU/mL)            Median            1108.0           446.0                   2000.0           0.001               
                               Range             4.5--185,072     4.5--51,851             9.0--185,072                         
  Total protein (g/dL)         Median            6.8              7.0                     6.7              0.027               
                               Range             4.8--9.3         5.4--8.5                4.8--9.3                             
  Albumin (g/dL)               Median            3.5              3.6                     3.4              0.015               
                               Range             2.4--4.9         2.5--4.8                2.4--4.9                             
  ALBI score                   Median            −2.18            −2.25                   −2.14            0.081               
                               Range             −3.55 to −0.64   −3.37 to −0.91          −3.55 to −0.64                       
  BMI (kg/m^2^)                Underweight       4                2.6                     0                0       4    4.0    0.000
                               Normal weight     104              66.7                    26               45.6    78   78.8   
                               Overweight        41               26.3                    25               43.9    16   16.2   
                               Obesity           7                4.5                     6                10.5    1    1.0    
  Previous treatment           Surgery           15               9.6                     7                12.3    8    8.1    0.392
                               Chemotherapy      15               9.6                     1                1.8     14   14.1   0.011
                               TACE/TACI/RFA     94               60.3                    37               64.9    57   57.6   0.367
                               None              55               35.3                    18               31.6    37   37.4   0.466
  RT aim                       Curative          113              72.4                    45               78.9    68   68.7   0.167
                               Palliative        43               27.6                    12               21.1    31   31.3   
  Treatment scheme             RT alone          75               48.1                    31               54.4    44   44.4   0.231
                               CCRT              81               51.9                    26               45.6    55   55.6   
  RT modality                  3D-CRT            52               33.3                    21               36.8    31   31.3   0.481
                               IMRT              104              66.7                    36               63.2    68   68.7   
  RT dose                      Median            52.1             52.9                    52.1             0.029               
  (EQD2, α/β = 10)             Range             30.0--125.0      40.0--125.0             30.0--99.2                           
  PTV (cc)                     Median            735.4            627.21                  829.37           0.017               
                               Range             15.0--5851.2     15.0--3347.1            30.3--5,851.2                        
  RT scheme                    Conventional RT   153              98.1                    55               96.5    98   99.0   0.554
                               SBRT              3                1.9                     2                3.5     1    1.0    

*HCC, Hepatocellular carcinoma; RT, Radiotherapy; HBV, Hepatitis B virus; HCV, Hepatitis C virus; AFP, Alpha-fetoprotein; PIVKA-II, Proteins induced by vitamin K absence or antagonist-II; ALBI, Albumin-bilirubin; BMI, Body mass index; TACE, Transcatheter arterial chemoembolization; TACI, Transcatheter arterial chemotherapy infusion; RFA, Radiofrequency ablation; CCRT, Concurrent chemoradiation therapy; 3D-CRT, 3-Dimensional conformal radiation therapy; IMRT, Intensity-modulated radiation therapy; EQD2, Equivalent dose in 2 Gy fractions; PTV, Planning target volume; SBRT, Stereotactic body radiotherapy*.

Of the 156 patients, 90 patients had stage IV disease, of whom 21 patients had distant metastasis. Most patients were Child-Pugh class A (*n* = 96, 61.5%) and few were Child-Pugh class C (*n* = 3, 1.9%). According to the BMI, patients with normal weight were the most frequent (*n* = 104, 66.7%), followed by those who were overweight (*n* = 41, 26.3%). Pre-RT sarcopenia group had higher PIVKA-II (*p* = 0.001), lower serum total protein level (*p* = 0.027), lower serum albumin level (*p* = 0.015), and lower percentage of overweight/obesity BMI (*p* \< 0.001). Although not statistically significant, pre-RT sarcopenic patients had poorer Child-Pugh class and more advanced stage.

Regarding treatment characteristics, 81 patients (51.9%) were treated with concurrent intra-arterial chemotherapy, and 75 patients (48.1%) were treated with RT alone. Most of the patients (*n* = 153, 98.1%) received conventional RT, and only three patients (1.9%) received SBRT. Median prescribed equivalent dose in 2 Gy fractions, assuming α/β = 10 (EQD210) was 52.1 Gy. Compared with the group without pre-RT sarcopenia, the pre-RT sarcopenia group had a higher percentage of patients with previous systemic chemotherapy (*p* = 0.011), lower total prescribed dose (*p* = 0.029), and larger PTV (*p* = 0.017). Pre-RT sarcopenic patients had more RT for palliative treatment than pre-RT non-sarcopenic patients, even though no statistically significant difference was found.

Analysis of Survival
--------------------

Over a median follow-up duration of 9.3 months (range 1.2--81.2 months), 125 patients died. Patients in the pre-RT sarcopenia group showed poorer OS than those in the pre-RT non-sarcopenia group (median OS: 7.1 months vs. 15.3 months, *p* \< 0.001; [Figure 2](#F2){ref-type="fig"}).

![Kaplan-Meier curves of overall survival in patients with or without pre-RT sarcopenia.](fonc-09-01075-g0002){#F2}

The evaluation of post-RT sarcopenia was available in 148 patients. Only four patients in pre-RT sarcopenia group had overcome the sarcopenia after RT. Among the 57 patients who did not have sarcopenia before RT, 20 developed sarcopenia after RT (35.1%). Compared to those without sarcopenia after RT (*n* = 35), these 20 patients showed significantly lower OS (median 14.1 vs. 17.5 months, *p* = 0.018, [Figure 3](#F3){ref-type="fig"}). The prognosis of these patients was as poor as those with sarcopenia before RT.

![Kaplan-Meier curves of overall survival in patients without pre-RT sarcopenia. Comparing overall survival between patients with newly developed sarcopenia after receiving RT and patients who still had no sarcopenia after RT. RT, radiotherapy.](fonc-09-01075-g0003){#F3}

Prognostic Factors for Survival
-------------------------------

The results of Cox proportional hazard regression analysis for OS are shown in [Table 2](#T2){ref-type="table"}. In univariate analysis, advanced stage at the time of RT (HR: 2.63; 95% CI: 1.28--5.40; *p* = 0.009); Child-Pugh classification B or C (HR: 1.46; 95% CI: 1.02--2.10; *p* = 0.041); higher AFP (HR: 1.63; 95% CI: 1.10--2.41; *p* = 0.015); lower serum albumin level (HR: 0.51; 95% CI: 0.35--0.73; *p* \< 0.001); higher ALBI score (HR: 2.01; 95% CI: 1.47--2.75; *p* \< 0.001); lower total dose of RT (HR: 0.45; 95% CI: 0.31--0.64; *p* \< 0.001); and larger PTV (HR: 1.02; 95% CI: 1.00--1.04; *p* = 0.021) were identified as poor prognostic factors for OS. Pre-RT sarcopenia (HR: 2.62; 95% CI: 1.76--3.89; *p* \< 0.001) was also significant for OS.

###### 

Univariate and multivariate analysis for OS.

                                                                                      **Overall survival**                               
  ----------------------------------------------------------------------------------- ---------------------- ------- ------------------- -------
  Age (\<65 vs. ≥65 years)                                                            0.98 (0.66--1.46)      0.92                        
  Sex (Male vs. Female)                                                               0.81 (0.50--1.31)      0.383                       
  Viral infection (No vs. Yes)                                                        1.28 (0.81--2.03)      0.30                        
  HCC stage (I + II vs. III + IV)                                                     2.63 (1.28--5.40)      0.00    1.75 (0.79--3.85)   0.166
  Portal vein tumor thrombus (No vs. Yes)                                             1.19 (0.83--1.72)      0.34                        
  Child-Pugh class (A vs. B + C)                                                      1.46 (1.02--2.10)      0.04    0.95 (0.60--1.52)   0.842
  AFP (\<20 ng/mL vs. ≥20 ng/mL)                                                      1.63 (1.10--2.41)      0.01    1.03 (0.65--1.64)   0.888
  PIVKA-II (\<40 mAU/mL vs. ≥40 mAU/mL)                                               1.37 (0.87--2.14)      0.17                        
  Total protein (\<6.0 g/dL vs. ≥6.0 g/dL)                                            0.73 (0.43--1.26)      0.264                       
  Albumin (\<3.4 g/dL vs. ≥3.4 g/dL)                                                  0.51 (0.35--0.73)      0.000   0.98 (0.55--1.75)   0.937
  ALBI score                                                                          2.01 (1.47--2.75)      0.000   2.35 (1.33--4.17)   0.003
  BMI (\<25 vs. ≥25 kg/m^2^)                                                          1.11 (0.78--1.59)      0.548                       
  Prior treatment                                                                                                                        
     Surgery                                                                          0.58 (0.31--1.08)      0.084   0.87 (0.44--1.74)   0.698
     Chemotherapy                                                                     1.63 (0.91--2.93)      0.099   0.87 (0.44--1.74)   0.900
     TACE or TACI or RFA                                                              1.13 (0.78--1.63)      0.512                       
  Treatment scheme (RT alone vs. CCRT)                                                1.09 (0.77--1.55)      0.637                       
  RT modality (3D CRT vs. IMRT + Tomo)                                                0.73 (0.51--1.06)      0.097   0.96 (0.58--1.58)   0.869
  Total dose (EQD2 \<52.1 Gy vs. ≥52.1 Gy)                                            0.45 (0.31--0.64)      0.000   0.44 (0.27--0.71)   0.001
  PTV                                                                                 1.02 (1.00--1.04)      0.021   1.01 (0.99--1.03)   0.399
  Pre-RT sarcopenia (no vs. yes)                                                      2.62 (1.76--3.89)      0.000   2.38 (1.53--3.70)   0.000
  Newly developed sarcopenia after RT (No vs. Yes)[^\*^](#TN1){ref-type="table-fn"}   2.16 (1.12--4.16)      0.021   2.53 (1.28--5.02)   0.008

*Univariate and multivariate analysis for overall survival in patients without pre-RT sarcopenia*.

*OS, overall survival; HR, Hazard ratio; CI, Confidence interval; HCC, Hepatocellular carcinoma; AFP, Alpha-fetoprotein; PIVKA-II, Proteins induced by vitamin K absence or antagonist-II; ALBI, Albumin-bilirubin; BMI, Body mass index; TACE, Transcatheter arterial chemoembolization; TACI, Transcatheter arterial chemotherapy infusion; RFA, Radiofrequency ablation; RT, Radiotherapy; CCRT, Concurrent chemoradiation therapy; 3D-CRT, 3-Dimensional conformal radiation therapy; IMRT, Intensity-modulated radiation therapy; EQD2, Equivalent dose in 2 Gy fractions; PTV, Planning target volume*.

Then we performed multivariate analysis; ALBI score (HR: 2.35; 95% CI: 1.33--4.17; *p* = 0.003); total dose \[hazard ratio (HR): 0.44; 95% CI: 0.27--0.71; *p* = 0.001); and pre-RT sarcopenia (HR: 2.38; 95% CI: 1.53--3.70; *p* \< 0.001) were identified as independent prognostic factors for OS.

In addition, univariate and multivariate analyses were performed in 57 patients without pre-RT sarcopenia. As a result, lower total dose (HR: 0.46; 95% CI: 0.24--0.89; *p* = 0.021), higher BMI (HR: 2.39; 95% CI: 1.22--4.71; *p* = 0.011), and newly developed sarcopenia after RT (HR: 2.53; 95% CI: 1.28--5.02; *p* = 0.008) significantly affected survival in both univariate and multivariate analyses.

Risk Factors for Newly Developed Sarcopenia After RT
----------------------------------------------------

We performed logistic regression analysis to investigate the risk factors associated with patients with newly developed sarcopenia after RT ([Table 3](#T3){ref-type="table"}). Older age \[odd ratio (OR): 310.19; *p* = 0.007\]; Child-Pugh classification B or C (OR: 15.24; *p* = 0.047); higher AFP (OR: 128.49; *p* = 0.008); higher PIVKA-II (OR: 118.54; *p* = 0.027); and larger PTV (OR: 51.31; *p* = 0.026) were significant factors for newly developed sarcopenia after RT.

###### 

Multivariate logistic regression analysis of newly developed sarcopenia after RT.

  **Risk factor**                           **Regression coefficient**   **Standard error**   **Wald χ^2^ value**   ***P*-value**   **Odds ratios (OR)**   **95% CI of OR**   
  ----------------------------------------- ---------------------------- -------------------- --------------------- --------------- ---------------------- ------------------ -----------
  Age (\<65 vs. ≥65 years)                  5.708                        2.121                7.240                 0.007           301.190                4.713              19249.211
  Sex (male vs. female)                     −4.467                       2.388                3.498                 0.061           0.011                  0.000              1.238
  Viral infection (No vs. Yes)              3.347                        1.833                3.334                 0.068           28.428                 0.782              1033.409
  HCC stage (I + II vs. III + IV)           −1.037                       2.463                0.177                 0.674           0.355                  0.003              44.254
  Portal vein tumor thrombus (No vs. Yes)   0.369                        1.458                0.064                 0.801           1.446                  0.083              25.206
  Child-Pugh class (A vs. B + C)            2.724                        1.370                3.951                 0.047           15.239                 1.039              223.539
  AFP (\<20 vs. ≥20 ng/mL)                  4.856                        1.819                7.129                 0.008           128.486                3.638              4537.747
  PIVKA-II (\<40 vs. ≥40 mAU/mL)            4.775                        2.164                4.868                 0.027           118.536                1.705              8242.149
  ALBI score                                1.489                        1.282                1.349                 0.245           4.433                  0.359              54.710
  NLR (\<4 vs. 4≥)                          −1.586                       1.437                1.218                 0.270           0.205                  0.012              3.422
  BMI (\<25 vs. ≥25 kg/m^2^)                −1.939                       1.445                1.801                 0.180           0.144                  0.008              2.442
  Prior local treatment (No vs. Yes)        0.897                        2.010                0.199                 0.655           2.452                  0.048              125.925
  RT aim (curative vs. palliative)          −1.497                       1.727                0.751                 0.386           0.224                  0.008              6.612
  Treatment scheme (RT alone vs. CCRT)      −1.412                       1.662                0.722                 0.396           0.244                  0.009              6.335
  RT modality (3D CRT vs. IMRT + Tomo)      2.063                        1.634                1.593                 0.207           7.866                  0.320              193.538
  Total dose (EQD2 \<52.1 vs. ≥52.1 Gy)     −1.564                       1.593                0.964                 0.326           0.209                  0.009              4.748
  PTV (\<500 vs. ≥500 cc)                   3.938                        1.765                4.979                 0.026           51.310                 1.614              1630.973

*RT, Radiotherapy; OR, Odds ratio; CI, Confidence interval; HCC, Hepatocellular carcinoma; AFP, Alpha-fetoprotein; PIVKA-II, Proteins induced by vitamin K absence or antagonist-II; ALBI, Albumin-bilirubin; NLR, Neutrophil-lymphocyte ratio; BMI, Body mass index; CCRT, Concurrent chemoradiation therapy; 3D-CRT, 3-Dimensional conformal radiation therapy; IMRT, Intensity-modulated radiation therapy; EQD2, Equivalent dose in 2 Gy fractions; PTV, Planning target volume*.

Discussion {#s4}
==========

We showed that sarcopenia is an independent factor affecting survival rates in HCC patients who have received RT to liver. In addition, pre-RT sarcopenia and newly developed sarcopenia after RT was significantly associated with poor survival. Patients who were older and had higher PIVKA-II level before treatment were more likely to develop sarcopenia after RT.

Recently, many hospitals have been using sarcopenia as a predictor of prognosis in cancer patients instead of cachexia, which better reflects nutrition and general condition. The European Working Group on Sarcopenia in the Elderly recommended the use of the presence of both reduced muscle mass and muscle function to identify sarcopenia ([@B25]). Methods for measuring muscle mass include measuring the total skeletal muscle mass using dual energy X-ray absorptiometry or obtaining L3-SMI through CT. Muscle function can be determined by measuring gait speed or handgrip strength. However, muscle function has the disadvantage of a difficult and subjective measurement, and several studies use only muscle mass measurement. In our study, we measured the skeletal muscle mass through CT, since this makes it easy to diagnose pre-RT sarcopenia, because the simulation CT is always taken for RT. If sarcopenia is observed on simulation CT performed for RT, we can expect that the prognosis of RT will be poor.

The hypothesis that liver disease induces sarcopenia has been reported in several studies. There are several studies showing that sarcopenia is significantly increased in patients who undergo surgery, received chemotherapy, or local therapy in HCC ([@B18]--[@B20]). Liver cirrhosis also has a similar relationship ([@B26]). Although the mechanism of this association has not been elucidated yet, low hepatic functional reserve and protein energy malnutrition due to liver disease may be the main causes of sarcopenia. In addition, reduced protein synthesis and degeneration of proteins by pro-inflammatory cytokines released from tumor cells may lead to a decrease in the amount of skeletal muscle mass. Our finding, which showed sarcopenia at a lower serum albumin and total protein level, may be attributed to protein energy malnutrition, consistent with previous studies ([@B18]--[@B20], [@B26]). However, Child-Pugh classification and ALBI score, which more accurately reflects liver function, did not differ between the two (Pre-RT sarcopenic and non-sarcopenic) groups ([Table 1](#T1){ref-type="table"}). In addition, higher PIVKA-II level, was presumed to be related to tumor burden, but the pathophysiological mechanism is also unknown. An additional biological approach would be needed to explain this result.

Chemotherapy, which is used for cancer treatment, is also suggested to induce sarcopenia by decreasing protein synthesis by expressing molecules (such as Ras, Raf, MEK, and ER) and decreasing proliferation of muscle-cell by expressing mTOR ([@B27], [@B28]). Like the observations in those studies, Pre-RT sarcopenia group had higher percentage of patients who underwent systemic chemotherapy before receiving RT in our study. Other studies have also shown that sarcopenia is significantly more frequent in advanced renal cell carcinoma or HCC patients with sorafenib, which is consistent with our findings ([@B29], [@B30]). However, in multivariate logistic regression analysis, previous systemic chemotherapy was not a significant factor, and this might have been due to the small number of patients who received chemotherapy prior to RT.

In some studies, sarcopenia has been suggested to be due to decreased appetite, general condition, and dysphagia ([@B31], [@B32]). In our study, sarcopenic patients have a lower BMI than non-sarcopenic patients. Because of this result, it may seem that there is no difference between sarcopenia and cachexia. However, sarcopenia and cachexia are independent because only about 4% of sarcopenic patients were underweight status (BMI \<18.5 kg/m^2^).

Several studies have also been published regarding the fact that sarcopenia causes poor prognosis in the treatment of cancer. Sarcopenia is significantly associated with prognosis of cancer treatment in colon, breast, lung, head and neck cancer, and HCC ([@B13]--[@B15]). Especially in HCC, prognosis is poor when sarcopenia is present in patients receiving surgery, chemotherapy, and or local therapy (TACE, TACI, RFA) ([@B18]--[@B20]). This tendency is found not only in HCC but also in liver diseases such as liver cirrhosis, hepatitis, and liver transplantation ([@B26], [@B33], [@B34]). Our study also showed that survival was significantly poor when sarcopenia accompanied HCC. The mechanism by which sarcopenia causes poor prognosis in cancer treatment is not yet known. At present, a possible mechanism is that sarcopenia may reduce muscle strength, resulting in poor physical performance, which may reduce tolerability for cancer treatment ([@B14]). In addition, another possible mechanism is that as the amount of stored protein decreases due to sarcopenia, the metabolism and immunity decrease proportionally to this, leading to a decrease in antitumor response and an increase in mortality ([@B35]). However, the molecular mechanism of sarcopenia remains poorly understood, and further studies are needed.

In our study, univariate and multivariate analyses of OS showed that ALBI score, total irradiated dose, and pre-RT sarcopenia were significant factors. OS was significantly better when the total dose was higher than EQD2 52.1 Gy (median dose), which was in line with previous findings ([@B36]).

Consistent with the hypothesis that the low hepatic functional reserve will cause sarcopenia, ALBI score was significantly associated with survival. Compared to Child-Pugh classification, which scores clinical measures including encephalopathy, ALBI only scores objective values (albumin and bilirubin). Therefore, other studies have recently shown that the ALBI score can be used to evaluate the liver function more accurately than Child-Pugh classification ([@B37], [@B38]).

Among those who did not have pre-RT sarcopenia, 20 patients had newly developed sarcopenia after receiving RT. These 20 patients were significantly older, higher Child-Pugh classification B or C, higher level of AFP and PIVKA-II, and larger PTV than in patients who still had no sarcopenia after RT. Older age effect seems to be accounted for by age-related degradation of metabolism and RT tolerance. AFP and PIVKA-II may also be related to tumor burden, but the pathophysiologic mechanism is still unknown. Child-Pugh classification is a factor that is related to liver function. The larger the PTV, the greater the effect on liver function. It is very important to set up the RT field in these patients because older age, decreased liver function, and larger tumor burden eventually decrease the patient\'s nutritional status and reduce the muscle mass. Similarly, the total functional liver volume in sarcopenia patients is small and should be considered in surgery, when resection is performed ([@B39]). Therefore, from the radiation oncologist\'s point of view, if the patient needs large volume treatment, there is need to confirm whether these conditions exist in the patients.

Patients with sarcopenia prior to RT, and those newly developing sarcopenia after RT had significantly lower OS than patients who had no sarcopenia before and after receiving RT. One possibility is that sarcopenia may occur due to low hepatic functional reserve induced by progression of HCC, which may result in lower OS. Therefore, in addition to patients who have already developed sarcopenia prior to RT, patients at high risk of sarcopenia after RT---that is those of older age, with Child-Pugh classification B or C, higher AFP and PIVKA-II, larger PTV, and poor prognostic factor of HCC---also need intensive nutritional support during RT to prevent the development of sarcopenia after treatment. According to the study conducted in our hospital, repetitive and intensive nutritional counseling is needed to improve the quality of life and prevent deterioration of nutritional status in patients with cancer around the head and neck, thorax, and abdomen receiving RT ([@B40]). Nutritional interventions in HCC are also expected to show good results in sarcopenia patients. In our prospective study on the effect of oral supplementation in HCC patients undergoing RT, we found that serum albumin levels increased significantly in the group given oral supplementation with branched-chain amino acid ([@B41]). Therefore, oral supplementation in patients receiving RT for HCC is very important, in terms of nutritional support. In our hospital, nutritional counseling is given to all patients regardless of sarcopenia before RT in HCC patients. This may likely improve survival rate in these patients.

One of the limitations of this study was that because of the retrospective analysis, not all variables and possible confounders could be assessed in all patients. In our study, pre-RT sarcopenic patients group was significantly larger in PTV than the non-sarcopenic group. Therefore, this result is probably related to the higher RT dose in non-sarcopenia patients. In Cox regression analysis to determine the OS-related prognostic factors ([Table 2](#T2){ref-type="table"}), RT dose had a significant effect on OS, but not PTV volume. In patients with low disease extent and good performance status, the treatment volume would be small and such patients could be given a high dose. Likewise, patients\' characteristics and treatment were heterogeneous, suggesting the possibility that various confounding factors may exist, which is considered a limitation of retrospective study.

There were also significant differences in previous chemotherapy, RT dose, serum albumin level, and total protein level between patients with and without pre-RT sarcopenia. This is because the degree of disease had varied considerably by the time the HCC patients reached the point of considering RT. However, there were no significant differences in indicators of liver function such as Child-Pugh classification and ALBI score. Moreover, there were no clinically significant differences between each of the two groups in [Table 1](#T1){ref-type="table"} (Pre-RT sarcopenic and non-sarcopenic) and [Supplementary Table 1](#SM1){ref-type="supplementary-material"} (Newly developed sarcopenic and sustained non-sarcopenic) characteristics. Nevertheless, these findings could be due to selection bias and unmeasured confounders and are considered to be the limitations of this study. Therefore, from a physician\'s point of view, efforts such as matching based on these factors may help to reduce the selection bias and unmeasured confounders. However, the disease status and treatment were too heterogeneous relative to the number of patients, making matching difficult. In addition, we did not analyze the treatment after RT, and further analysis is needed because it may also affect prognosis. Nonetheless, this study is one of the largest analyses to assess the prognostic significance of sarcopenia in patients with HCC who received RT. Also, as far as we know, the strength of this study is that it is one of the few studies that analyzed the prognostic significance of sarcopenia in cancer patients receiving RT, especially in patients with HCC.

Conclusion {#s5}
==========

In conclusion, the findings of this study suggest that sarcopenia is frequent in patients with HCC, especially in those with lower liver function, higher tumor markers, and larger PTV; thus, these patients are more likely to develop sarcopenia after RT. Thus, the RT field should be carefully determined for these patients from the point of view of the radiation oncologist. Assessment of skeletal muscle depletion by CT imaging is an objective tool useful for diagnosing sarcopenia. In addition, pre-RT sarcopenia and newly developed sarcopenia after RT, as determined by simulation CT for RT, was significantly associated with poorer OS in HCC patients. Early intervention such as nutritional support and exercise therapies could prevent muscle wasting and could be effective in improving the prognosis of HCC patients. Prospective studies are needed to clarify optimum reference values of sarcopenia for predicting cancer-specific outcomes for HCC patients.
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